LiPlasome Pharma Plc.

LiPlasome Pharma Plc. is a Danish biotech company focused on cancer therapy. The company has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). Thus, a targeted treatment limiting the destruction of healthy cells as well as side effects.

LiPlasome's technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. The company's first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. For futher information: